UK researchers successfully reversed T-cell acute lymphoblastic leukaemia, an aggressive blood cancer, using gene-edited immune cells for first time. This therapy, called BE-CAR7, modifies immune cells (T-cells) to have chimeric antigen receptors (CARs) on surface. The CARs recognise and target a specific protein on cancer cells' surface and the T-cell attached then destroys that cancer cell.